Illumina rival says patent verdict may lead to competition sooner

A jury verdict invalidating one of Illumina’s DNA-sequencing patents may allow a rival to enter the US market at an earlier date, likely influencing ongoing antitrust litigation between both companies and possibly also the Federal Trade Commission's complaint against Illumina's tie-up with Grail.


Get unlimited access to all Global Competition Review content